EGFR and head and neck squamous cell carcinoma: EGFR (or HER1) has particularly been shown to be highly expressed in most HNSCCs, leading to the investigation and approval of cetuximab, an anti-EGFR monoclonal antibody, for locally-advanced and R/M HNSCC irrespective of HPV status [180,181].